Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 24:24:100553.
doi: 10.1016/j.lana.2023.100553. eCollection 2023 Aug.

Living kidney donors with HIV: experience and outcomes from a case series by the HOPE in Action Consortium

Christine M Durand  1 , Nina Martinez  2 , Karl Neumann  3 , Reed C Benedict  4 , Arthur W Baker  5 , Cameron R Wolfe  5 , Valentina Stosor  6 , Aneesha Shetty  6 , Zachary C Dietch  6 , Leah Goudy  6 , Michelle A Callegari  6 , Allan B Massie  7 , Diane Brown  1 , Willa Cochran  1 , Abimereki Muzaale  8 , Derek Fine  1 , Aaron A R Tobian  9 , Cheryl A Winkler  10 , Fawaz Al Ammary  1 , Dorry L Segev  7 ; HOPE in Action Investigators
Collaborators, Affiliations

Living kidney donors with HIV: experience and outcomes from a case series by the HOPE in Action Consortium

Christine M Durand et al. Lancet Reg Health Am. .

Abstract

Background: Living kidney donation is possible for people living with HIV (PLWH) in the United States within research studies under the HIV Organ Policy Equity (HOPE) Act. There are concerns that donor nephrectomy may have an increased risk of end-stage renal disease (ESRD) in PLWH due to HIV-associated kidney disease and antiretroviral therapy (ART) nephrotoxicity. Here we report the first 3 cases of living kidney donors with HIV under the HOPE Act in the United States.

Methods: Within the HOPE in Action Multicenter Consortium, we conducted a prospective study of living kidney donors with HIV. Pre-donation, we estimated the 9-year cumulative incidence of ESRD, performed genetic testing of apolipoprotein L1 (APOL1), excluding individuals with high-risk variants, and performed pre-donation kidney biopsies (HOPE Act requirement). The primary endpoint was ≥grade 3 nephrectomy-related adverse events (AEs) in year one. Post-donation, we monitored glomerular filtration rate (measured by iohexol/Tc-99m DTPA [mGFR] or estimated with serum creatinine [eGFR]), HIV RNA, CD4 count, and ART.

Findings: There were three donors with two-four years of follow-up: a 35 year-old female, a 52 year-old male, and a 47 year-old male. Pre-donation 9-year estimated cumulative incidence of ESRD was 3.01, 8.01, and 7.76 per 10,000 persons, respectively. In two donors with APOL1 testing, no high-risk variants were detected. Biopsies from all three donors showed no kidney disease. Post-donation, two donors developed nephrectomy-related ≥grade 3 AEs: a medically-managed ileus and a laparoscopically-repaired incisional hernia. GFR declined from 103 to 84 mL/min/1.73 m2 at four years (mGFR) in donor 1, from 77 to 52 mL/min/1.73 m2 at three years (eGFR) in donor 2, and from 65 to 39 mL/min/1.73 m2 at two years (eGFR) in donor 3. HIV RNA remained <20 copies/mL and CD4 count remained stable in all donors.

Interpretation: The first three living kidney donors with HIV under the HOPE Act in the United States have had promising outcomes at two-four years, providing proof-of-concept to support living donation from PLWH to recipients with HIV.

Funding: National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Keywords: HIV Organ Policy Equity Act; HIV donation; HIV to HIV transplantation; HOPE Act; Living kidney donation; Transplantation from donors with HIV to recipients with HIV.

PubMed Disclaimer

Conflict of interest statement

DLS reports serving as a consultant and receiving honoraria for speaking from AstraZeneca, Novavax, Novartis, CareDx, Transmedics, Sanofi, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, and Thermo Fisher Scientific. CMD reports serving on a grant review committee for Gilead Sciences. AS reports serving on an advisory board for Veloxis Pharmaceuticals. All other authors of this manuscript have no conflicts of interest to disclose as described by The Lancet.

References

    1. Abraham A.G., Althoff K.N., Jing Y., et al. End-stage renal disease among HIV-infected adults in North America. Clin Infect Dis. 2015;60(6):941–949. - PMC - PubMed
    1. Bickel M., Marben W., Betz C., et al. End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years. HIV Med. 2013;14(3):127–135. - PubMed
    1. Trullas J.C., Cofan F., Barril G., et al. Outcome and prognostic factors in HIV-1-infected patients on dialysis in the cART era: a GESIDA/SEN cohort study. J Acquir Immune Defic Syndr. 2011;57(4):276–283. - PubMed
    1. Razzak Chaudhary S., Workeneh B.T., Montez-Rath M.E., Zolopa A.R., Klotman P.E., Winkelmayer W.C. Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy. Nephrol Dial Transplant. 2015;30(10):1734–1740. - PMC - PubMed
    1. Al Ammary F., Bowring M.G., Massie A.B., et al. The changing landscape of live kidney donation in the United States from 2005 to 2017. Am J Transplant. 2019;19(9):2614–2621. - PMC - PubMed